N-terminal pro-brain natriuretic peptide is associated with pulmonary hypertension or diastolic dysfunction in patients with systemic sclerosis: An Australian prospective cross-sectional study.

IF 1.4 Q3 RHEUMATOLOGY
Francis J Ha, Zoe Brown, Wendy Stevens, David Prior, Laura Ross, Nava Ferdowsi, Mandana Nikpour, Andrew T Burns
{"title":"N-terminal pro-brain natriuretic peptide is associated with pulmonary hypertension or diastolic dysfunction in patients with systemic sclerosis: An Australian prospective cross-sectional study.","authors":"Francis J Ha, Zoe Brown, Wendy Stevens, David Prior, Laura Ross, Nava Ferdowsi, Mandana Nikpour, Andrew T Burns","doi":"10.1177/23971983241249209","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pulmonary arterial hypertension and left ventricular diastolic dysfunction are associated with significant morbidity and mortality in systemic sclerosis. N-terminal pro-brain natriuretic peptide has been proposed as part of composite screening algorithms for pulmonary arterial hypertension. Our aim was to assess the prevalence of pulmonary hypertension and diastolic dysfunction, and evaluate their association with serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients.</p><p><strong>Methods: </strong>Patients with systemic sclerosis were prospectively enrolled to undergo N-terminal pro-brain natriuretic peptide testing and transthoracic echocardiography at a tertiary Australian centre from January to October 2022. We collected demographic and transthoracic echocardiography variables including pulmonary hypertension estimated by tricuspid regurgitant velocity and diastolic dysfunction assessed by the ASE/EACVI 2016 guidelines. Pearson's correlation coefficient was used to evaluate association between N-terminal pro-brain natriuretic peptide and echocardiographic parameters.</p><p><strong>Results: </strong>Sixty-one patients were enrolled (median age = 62 years (interquartile range = 55-69 years); 84% female). Two-thirds of patients had limited systemic sclerosis (40/61). Five patients (8%) had high likelihood of pulmonary hypertension by transthoracic echocardiography. Seven patients (11%) had diastolic dysfunction; however, seven patients (11%) had indeterminate diastology. Six patients underwent right heart catheterisation, with five patients diagnosed with pulmonary hypertension. N-terminal pro-brain natriuretic peptide in patients with pulmonary hypertension or diastolic dysfunction was significantly higher (median = 207 and 226 pg/mL, respectively) compared to patients without either condition (median = 69 pg/mL, p = 0.01). N-terminal pro-brain natriuretic peptide showed a statistically significant although limited correlation with estimated pulmonary pressures measured by tricuspid regurgitant velocity (r = 0.44, p = 0.002) and left ventricular filling pressures (r = 0.27, p = 0.04).</p><p><strong>Conclusion: </strong>Pulmonary hypertension and diastolic dysfunction are both observed in systemic sclerosis. N-terminal pro-brain natriuretic peptide is associated with both conditions; however, it cannot distinguish between the two disease processes. Right heart catheterisation may be required to make this distinction.</p>","PeriodicalId":17036,"journal":{"name":"Journal of Scleroderma and Related Disorders","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457770/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Scleroderma and Related Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23971983241249209","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Pulmonary arterial hypertension and left ventricular diastolic dysfunction are associated with significant morbidity and mortality in systemic sclerosis. N-terminal pro-brain natriuretic peptide has been proposed as part of composite screening algorithms for pulmonary arterial hypertension. Our aim was to assess the prevalence of pulmonary hypertension and diastolic dysfunction, and evaluate their association with serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients.

Methods: Patients with systemic sclerosis were prospectively enrolled to undergo N-terminal pro-brain natriuretic peptide testing and transthoracic echocardiography at a tertiary Australian centre from January to October 2022. We collected demographic and transthoracic echocardiography variables including pulmonary hypertension estimated by tricuspid regurgitant velocity and diastolic dysfunction assessed by the ASE/EACVI 2016 guidelines. Pearson's correlation coefficient was used to evaluate association between N-terminal pro-brain natriuretic peptide and echocardiographic parameters.

Results: Sixty-one patients were enrolled (median age = 62 years (interquartile range = 55-69 years); 84% female). Two-thirds of patients had limited systemic sclerosis (40/61). Five patients (8%) had high likelihood of pulmonary hypertension by transthoracic echocardiography. Seven patients (11%) had diastolic dysfunction; however, seven patients (11%) had indeterminate diastology. Six patients underwent right heart catheterisation, with five patients diagnosed with pulmonary hypertension. N-terminal pro-brain natriuretic peptide in patients with pulmonary hypertension or diastolic dysfunction was significantly higher (median = 207 and 226 pg/mL, respectively) compared to patients without either condition (median = 69 pg/mL, p = 0.01). N-terminal pro-brain natriuretic peptide showed a statistically significant although limited correlation with estimated pulmonary pressures measured by tricuspid regurgitant velocity (r = 0.44, p = 0.002) and left ventricular filling pressures (r = 0.27, p = 0.04).

Conclusion: Pulmonary hypertension and diastolic dysfunction are both observed in systemic sclerosis. N-terminal pro-brain natriuretic peptide is associated with both conditions; however, it cannot distinguish between the two disease processes. Right heart catheterisation may be required to make this distinction.

N端前脑钠肽与系统性硬化症患者的肺动脉高压或舒张功能障碍有关:一项澳大利亚前瞻性横断面研究。
导言:肺动脉高压和左心室舒张功能障碍与系统性硬化症的重大发病率和死亡率有关。N 端前脑钠肽已被提议作为肺动脉高压复合筛查算法的一部分。我们的目的是评估系统性硬化症患者肺动脉高压和舒张功能障碍的患病率,并评估它们与血清 N 末端前脑钠尿肽的关系:2022年1月至10月,澳大利亚一家三级医疗中心前瞻性地招募了系统性硬化症患者,让他们接受N末端前脑钠尿肽检测和经胸超声心动图检查。我们收集了人口统计学和经胸超声心动图变量,包括根据三尖瓣反流速度估测的肺动脉高压和根据 ASE/EACVI 2016 指南评估的舒张功能障碍。皮尔逊相关系数用于评估N末端前脑钠尿肽与超声心动图参数之间的关联:61名患者入选(中位年龄=62岁(四分位间范围=55-69岁);84%为女性)。三分之二的患者患有局限性系统性硬化(40/61)。通过经胸超声心动图检查,五名患者(8%)极有可能患有肺动脉高压。七名患者(11%)有舒张功能障碍;但有七名患者(11%)舒张功能不确定。六名患者接受了右心导管检查,其中五名患者被诊断为肺动脉高压。肺动脉高压或舒张功能障碍患者的 N 端前脑钠肽含量(中位数分别为 207 和 226 pg/mL)明显高于无这两种情况的患者(中位数为 69 pg/mL,P = 0.01)。N-末端前脑钠肽与三尖瓣反流速度(r = 0.44,p = 0.002)和左室充盈压(r = 0.27,p = 0.04)测得的估计肺压有统计学意义,但相关性有限:结论:系统性硬化症患者会出现肺动脉高压和舒张功能障碍。结论:系统性硬化症患者可同时出现肺动脉高压和舒张功能障碍,N末端脑钠肽与这两种病症均有关联,但不能区分这两种疾病。要进行区分,可能需要进行右心导管检查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
31
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信